Medexus Pharmaceuticals Inc (FRA:P731)

Q2 2026 Medexus Pharmaceuticals Inc Earnings Call Transcript

Nov 13, 2025 / 01:00 PM GMT

Release Date Price: €1.73 (+9.49%)

Transcript

Key Points

Positve

Graphopex's commercial launch has exceeded pre-launch expectations, with significant patient demand and engagement from 83% of US transplant centers.
Graphopex is expected to contribute positively to quarterly operating cash flows by the fourth calendar quarter of 2025.
The NTA program's additional reimbursement for Graphopex under Medicare is expected to enhance adoption and utilization.
Medexus Pharmaceuticals Inc (MEDXF) achieved positive operating income and adjusted EBITDA growth for the second consecutive fiscal quarter.
The company has successfully reduced the product-level cost of goods for Xfinity by 30% since fiscal Q1 2021.

Negative

Fiscal Q226 net revenue decreased to $24.7 million from $26.3 million in the same period last year.
Adjusted EBITDA decreased to $4.4 million from $6 million in the same period last year.
Net loss for the quarter was $0.3 million, compared to a net income of $0.1 million in the same period last year.
Unit demand for Resuvo in the United States and Meadowjack in Canada decreased by 2% and 9%, respectively, over the trailing 12-month period.
Rupel continues to face significant generic competition in Canada, leading to a 58% decrease in unit demand over the three-month period ending September 30th.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MDP.TO - Medexus Pharmaceuticals Inc
Q2 2026 Medexus Pharmaceuticals Inc Earnings Call
Nov 13, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everyone and welcome to the Medexus Pharmaceuticals second quarter 2026 conference call.

At this time, all participants have been placed on a listen-only mode, and the floor will be open for questions following the presentation. If anyone should require operator assistance during this conference, please press 0 on your phone keypad. Please note this conference is being recorded.

I will now turn the conference over to your host, Victoria Rutherford, Investor relations. Victoria, the floor is yours.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.